NCT05847634 Depth of Sedation and Its Impact on Cerebrovascular Reactivity in Acute Respiratory Distress Syndrome: a Pilot Analysis
| NCT ID | NCT05847634 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manitoba |
| Condition | ARDS, Human |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-11-25 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-11-25 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigation of the feasibility of monitoring processed transcutaneous electroencephalography (EEG), a method of interpreting brain activity, and near-infrared spectroscopy (NIRS), a method of determining levels of tissue oxygenation (StO2) in the brain, for patients with acute respiratory distress syndrome (ARDS) in the ICU.
Eligibility Criteria
Inclusion Criteria: * Adult patient admitted to the ICU * ARDS confirmed according to the Berlin Definition * Invasive mechanical ventilation * Deep sedation and/or neuromuscular blockade required for ARDS treatment at the discretion of the treating medical team * Application of monitoring devices feasible Exclusion Criteria: * More than 24 hours elapsed since ICU admission * Death is deemed imminent and inevitable during the next 24 hours * Known allergy to a textile component of the device * Consent declined from patient or authorized third party * The treating clinician believes that participation in the study would not be in the best interest of the patient
Contact & Investigator
Asher Mendelson, MD PhD
PRINCIPAL INVESTIGATOR
University of Manitoba
Frequently Asked Questions
Who can join the NCT05847634 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ARDS, Human. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05847634 currently recruiting?
Yes, NCT05847634 is actively recruiting participants. Contact the research team at asher.mendelson@umanitoba.ca for enrollment information.
Where is the NCT05847634 trial being conducted?
This trial is being conducted at Winnipeg, Canada.
Who is sponsoring the NCT05847634 clinical trial?
NCT05847634 is sponsored by University of Manitoba. The principal investigator is Asher Mendelson, MD PhD at University of Manitoba. The trial plans to enroll 40 participants.